PDCD1 and hepatocellular carcinoma: In another study, Shen et al. reported on 36 hepatocellular carcinoma (HCC) patients who were administered anti-PD-1/PD-L1 as monotherapy or in combination with an antiangiogenic agent (bevacizumab or sorafenib).